We claim:

1. A targeted immunocytokine for use in the treatment or inhibition of the growth of a tumor in a subject in combination with a TAAxCD3 bispecific antibody, wherein:
(a) a subject with cancer is to be selected; and
(b) a therapeutically effective amount of the targeted immunocytokine in combination with a therapeutically effective amount of the TAAxCD3 bispecific antibody is to be administered to the subject,

wherein the combination to be administered leads to increased anti-tumor efficacy, as compared to a subject to be administered the targeted immunocytokine as monotherapy.

2. A TAAxCD3 bispecific antibody for use in the treatment or inhibition of the growth of a tumor in a subject in combination with a targeted immunocytokine, wherein:
(a) a subject with cancer is to be selected; and
(b) a therapeutically effective amount of the TAAxCD3 bispecific antibody in combination with a therapeutically effective amount of the targeted immunocytokine is to be administered to the subject,

wherein the combination to be administered leads to increased anti-tumor efficacy, as compared to a subject to be administered the targeted immunocytokine as monotherapy.

3. A pharmaceutical composition comprising a targeted immunocytokine and a TAAxCD3 bispecific antibody for use in the treatment or inhibition of the growth of a tumor in a subject, wherein:
(a) a subject with cancer is to be selected; and
(b) the pharmaceutical composition is to be administered to the subject,

wherein the combination to be administered leads to increased anti-tumor efficacy, as compared to a subject to be administered the targeted immunocytokine as monotherapy.

4. The targeted immunocytokine for use according to claim 1, the TAAxCD3 bispecific antibody for use according to claim 2, or the pharmaceutical composition for use according to claim 3, wherein the targeted immunocytokine comprises a fusion protein comprising (i) an immunoglobulin antigen-binding domain of a checkpoint inhibitor and (ii) an IL2 moiety, optionally wherein the checkpoint inhibitor is an inhibitor of PD1, PD-L1, PD-L2, LAG-3, CTLA-4,

TIM3, A2aR, B7H1, BTLA, CD160, LAIR1, TIGHT, VISTA, or VTCN1, further optionally wherein the checkpoint inhibitor is an inhibitor of PD1.

5. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to claim 4, wherein the IL2 moiety comprises: IL2 receptor alpha (IL2Ra) or a fragment thereof; and IL2 or a fragment thereof.

6. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to claim 4 or 5, wherein:

(a) the Ig antigen-binding domain of the checkpoint inhibitor comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 1, 11 and 20 and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) selected from the group consisting of SEQ ID NOs: 5 and 15; or

(b) the Ig antigen-binding domain of the checkpoint inhibitor comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) and three light chain CDRs (LCDR1, LCDR2, and LCDR3), wherein:

HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 2, 3, 4, 6, 7, and 8, respectively;

HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 12, 13, 14, 16, 7, and 17, respectively; or

HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 21, 22, 23, 6, 7, and 8, respectively.

7. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 4-6, wherein the antigen-binding domain of the checkpoint inhibitor comprises a HCVR/LCVR amino acid sequence pair selected from SEQ ID NOs: 1/5, 11/15, and 20/5, optionally wherein the antigen-binding domain of the checkpoint inhibitor comprises a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 20/5.

8. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 4-7, wherein the fusion protein comprises:

(a) a heavy chain comprising a HCVR and a heavy chain constant region of IgG1 or IgG4 isotype; and/or

(b) a heavy chain and a light chain, wherein:

the heavy chain comprises the amino acid sequence of SEQ ID NO: 24, and the light chain comprises the amino acid sequence of SEQ ID NO: 25;
the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, and the light chain comprises the amino acid sequence of SEQ ID NO: 10; or
the heavy chain comprises the amino acid sequence of SEQ ID NO: 18, and the light chain comprises the amino acid sequence of SEQ ID NO: 19.

9. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to claim 8, wherein the IL2 moiety is attached to the C-terminus of the heavy chain via a linker comprising the amino acid sequence of SEQ ID NO: 30 or 31.

10. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 4-9, wherein the IL2 moiety comprises:

(a) IL2 having the amino acid sequence of SEQ ID NO: 29;
(b) the IL2 or fragment thereof connected via a linker to the C-terminus of the IL2Ra or fragment thereof, optionally wherein the IL2Ra or fragment thereof comprises the amino acid sequence of SEQ ID NO: 28; and/or
(c) the amino acid sequence of SEQ ID NO: 27.

11. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 1-10, wherein the TAA of the TAAxCD3 bispecific antibody is selected from AFP, ALK, BAGE proteins, BCMA, BIRC5 (survivin), BIRC7, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CALR, CCR5, CD19, CD20 (MS4A1), CD22, CD30, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EpCAM, EphA2, Fra-1, FOLR1, GAGE proteins (*e.g.*, GAGE-1, -2), GD2, GD3, GloboH, glypican-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MAGE proteins (*e.g.*, MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, STEAP1, STEAP2, TAG-72, TGF-β, TMPRSS2, Thompson-nouvelle antigen (Tn), TRP-1, TRP-2, tyrosinase, and uroplakin-3.

12. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 1-11, wherein the TAA is MUC16.

13. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to claim 12, wherein the MUC16xCD3 bispecific antibody is a bispecific antibody or antigen-binding fragment thereof that comprises a first binding arm that binds specifically to CD3 comprising three heavy chain complementarity determining regions (CDRs) (A1-HCDR1, A1-HCDR2 and A1-HCDR3) contained within a heavy chain variable region (HCVR) having an amino acid sequence of SEQ ID NO: 34 and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO: 39; and a second binding arm that binds specifically to MUC16 comprising three heavy chain complementarity determining regions (CDRs) (A2-HCDR1, A2-HCDR2 and A2-HCDR3) contained within a HCVR having an amino acid sequence of SEQ ID NO: 44 and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a LCVR having an amino acid sequence of SEQ ID NO: 39, optionally wherein

(a) the A1-HCDR1, A1-HCDR2, A1-HCDR3, LCDR1, LCDR2, LCDR3, A2-HCDR1, A2-HCDR2, A2-HCDR3, LCDR1, LCDR2, and LCDR3 of the MUC16xCD3 bispecific antibody or antigen-binding fragment thereof of the second therapy comprises the amino acid sequences of SEQ ID NOs: 35, 36, 37, 40, 41, 42, 45, 46, 47, 40, 41, and 42, respectively;

(b) the MUC16xCD3 bispecific antibody or antigen-binding fragment thereof comprises (i) a first binding arm comprising a HCVR comprising the amino acid sequence of SEQ ID NO: 34 and/or a LCVR comprising the amino acid sequence of SEQ ID NO: 39 and (ii) a second binding arm comprising a HCVR comprising the amino acid sequence of SEQ ID NO: 44 and/or a LCVR comprising the amino acid sequence of SEQ ID NO: 39;

(c) the MUC16xCD3 bispecific antibody or antigen-binding fragment thereof comprises first binding arm comprising a heavy chain and a light chain, wherein the heavy chain has an amino acid sequence of SEQ ID NO: 33 and/or the light chain has an amino acid sequence of SEQ ID NO: 38; and a second binding arm comprising a heavy chain and a light chain, wherein the heavy chain has an amino acid sequence of SEQ ID NO: 43 and/or the light chain has an amino acid sequence of SEQ ID NO: 38; or

(d) the MUC16xCD3 bispecific antibody or antigen-binding fragment thereof is BSMUC16/CD3-001.

14. The targeted immunocytokine, the TAAxCD3 bispecific antibody or the pharmaceutical composition for use according to any one of claims 1-13, wherein the cancer is selected from

anal cancer, angiosarcoma, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, cholangiocarcinoma, chondrosarcoma, colon cancer, colorectal cancer, cutaneous squamous cell carcinoma, endometrial cancer, esophageal cancer, glioblastoma multiforme, head and neck squamous cell cancer, hepatocellular carcinoma, kidney cancer, liver cancer, lung cancer, Merkel cell carcinoma, melanoma, myeloma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, salivary gland cancer, skin cancer, soft tissue sarcoma, stomach cancer, testicular cancer, and uterine cancer.

15. The targeted immunocytokine or the TAAxCD3 bispecific antibody for use according to any one of claims 1, 2 or 4-14, wherein the targeted immunocytokine is to be administered to the subject:

(a) before or concurrently with the TAAxCD3 bispecific antibody to be administered; or

(b) after the TAAxCD3 bispecific antibody to be administered.